Madras HC Upholds Centre's One-Year Contract Extension of DCGI Susmita Roy13 Jan 2026 9:03 PM ISTNew Delhi: One of the most closely watched controversies in India's pharmaceutical sector last year, surrounding the continuation of the Drugs...
CDSCO Panel Backs Label Change Allowing Endocrinologists, Rheumatologists to Prescribe Amgen's Romosozumab Parthika Patel12 Jan 2026 9:12 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO), has recommended approval for amending the...
Zydus Lifesciences Gets CDSCO Panel Nod to Market Semaglutide Injection for Type 2 Diabetes Susmita Roy9 Jan 2026 11:45 PM ISTNew Delhi: Drug major Zydus Lifesciences Limited has received a key regulatory clearance from the Subject Expert Committee (SEC) functioning under the...
Zydus Gets CDSCO Panel Nod to Conduct Phase IV Study of Nelarabine Injection Parthika Patel5 Jan 2026 5:36 PM ISTNew Delhi: The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of permission to Zydus...
Alkem Secures CDSCO Panel Approval for Synthetic Semaglutide in Obesity Management Susmita Roy2 Jan 2026 5:48 PM ISTNew Delhi: Drug major Alkem Laboratories Limited has received a key regulatory clearance from the Subject Expert Committee (SEC) functioning under the...
Sun Pharma Gets CDSCO Panel Nod to Market Semaglutide Injection in Weight Loss Indication Susmita Roy1 Jan 2026 5:06 PM ISTNew Delhi: Drug major Sun Pharmaceutical Industries Limited has received a key regulatory clearance from the Subject Expert Committee (SEC)...
GeneSys Biologics Gets SEC Nod to Market Insulin Glargine, Phase IV Study Mandated Susmita Roy31 Dec 2025 11:25 AM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has granted permission to GeneSys...
CDSCO Panel Seeks Revised Phase IV Trial Protocol for MSN Lab's Nelarabine Injection Parthika Patel31 Dec 2025 11:19 AM ISTNew Delhi: Highlighting the need for stronger post-marketing safety oversight, the Subject Expert Committee (SEC) of the Central Drugs Standard...
Cipla Gets CDSCO Panel Nod to Begin Phase III Study of Semaglutide Injection Susmita Roy30 Dec 2025 2:27 PM ISTNew Delhi: Drug major Cipla Limited has received clearance from the Subject Expert Committee (SEC) functioning under the Central Drugs Standard...
CDSCO Cancels Import Registration of Cosmetic Hair Product Marketed as Drug Susmita Roy27 Dec 2025 9:00 PM ISTNew Delhi: In a significant regulatory action reinforcing the strict demarcation between cosmetics and drugs, the Central Drugs Standard Control...
Expert Panel Asks Ekam Pharma to Submit Global Prescribing Information Before Diazoxide 25 mg Clearance Susmita Roy27 Dec 2025 8:37 PM ISTNew Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO) has opined that Ekam Pharma...
CDSCO Expert Panel Accepts Phase IV Safety Data for Eisai Pharma's Lenvatinib Capsules Susmita Roy26 Dec 2025 9:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the Phase IV clinical trial...
